Gene therapy in status epilepticus

  title={Gene therapy in status epilepticus},
  author={Matthew C. Walker and Stephanie Schorge and Dimitri Michael Kullmann and Robert C. Wykes and Joost H. Heeroma and Laura Mantoan},
Gene therapy in human disease has expanded rapidly in recent years with the development of safer and more effective viral vectors, and presents a novel approach to the treatment of epilepsy. Studies in animals models have demonstrated that overexpression of inhibitory peptides can modify seizure threshold, prevent the development of epilepsy, and modify established epilepsy. More recently there has been a flurry of studies using optogenetics in which light‐activated channels expressed in… 
Investigational Treatments for Status Epileptics
This chapter focuses on antiseizure medications in clinical trials, the somewhat more remote prospect of gene therapy, and transcranial magnetic stimulation.
Concise Review: Prospects of Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells for Treating Status Epilepticus and Chronic Epilepsy
This concise review evaluates the current knowledge and outlook pertaining to MNC and MSC therapies for SE and chronic epilepsy and discusses the behavior of these cells in animal models of SE and their efficacy to restrain neurodegeneration, inflammation, and epilepsy.
Antiepileptic Drug Discovery
Psychological approaches in rodents support that neuroinfl ammation is involved in modulating seizure susceptibility, neuronal damage, and other neurological disorders associated with epilepsy.
Deneysel epilepsi modelinde KCNQ1 ve KCNQ3 genlerinin ekspresyon düzeyleri
Determining the changes in mRNA expression levels of genes encoding K+ ion channels will help to better understand the pathological mechanisms that occur during epilepsy.
Tumor‐related epilepsy and epilepsy surgery
There are relatively few recent literature resources on TRE that provide neurologists, neurosurgeons, epileptologists, and oncologists with an up‐to‐date, state‐of‐the‐art review of the field in all of its important aspects.
Specific conventional epileptic crisis
The article focuses on the cases of the seizure, order and behavior during and after the epileptic crisis, the child’s febrile convulsions and recommendations.
Epilepsy priorities in Europe: A report of the ILAE‐IBE Epilepsy Advocacy Europe Task Force
Recommendations that emerged at ERF2013 about how to strengthen epilepsy research, reduce the treatment gap, and reduce the burden and stigma associated with epilepsy are provided.
Épilepsie partielle continue : étude vidéo-EEG et évolution à partir d'une série de 28 patients
Cette etude est la plus grande serie de cas d’EPC tous documentes par VEEG, ainsi que le traitement etiologique, which permis de reduire les insuffisances liees au caractere retrospectif de cette andude, en confirmant le diagnostic d”EPC et en ecartant les diagnostics differentiels.


Optogenetic and Potassium Channel Gene Therapy in a Rodent Model of Focal Neocortical Epilepsy
Light-activated gene therapy acutely suppresses seizures, and gene therapy with a potassium channel prevents epileptogenesis and treats established epilepsy in a rodent model are used to suppress seizures acutely, prevent their occurrence after an epileptogenic stimulus, and successfully treat established focal epilepsy.
Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy.
The data show that this gene therapy strategy decreases spontaneous seizures and suppresses their progression in chronic epileptic rats, thus representing a promising new therapeutic strategy.
Adenosine augmentation therapies (AATs) for epilepsy: Prospect of cell and gene therapies
Optogenetic control of epileptiform activity
It is proved a principle, that selective hyperpolarization of principal cortical neurons by NpHR is sufficient to curtail paroxysmal activity in transduced neurons and can inhibit stimulation train-induced bursting in hippocampal organotypic slice cultures, which represents a model tissue of pharmacoresistant epilepsy.
Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion
Seizure disorders present an attractive gene therapy target, particularly because viral vectors such as adeno-associated virus (AAV) and lentivirus can stably transduce neurons. When we targeted the
Gene Therapy for Human Genetic Disease?
A sustained effort is proposed to be made to formulate a complete set of ethicoscientific criteria to guide the development and clinical application of gene therapy techniques, which could go a long way toward ensuring that gene therapy is used in humans only in those instances where it will prove beneficial, and toward preventing its misuse through premature application.
Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms
On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy
It is demonstrated that spontaneous temporal lobe seizures can be detected and terminated by modulating specific cell populations in a spatially restricted manner and a clinical approach built on these principles may overcome many of the side-effects of currently available treatment options.
The controversial role of adenoviral-derived vectors in gene therapy programs: where do we stand?
Adenoviral-mediated gene transfer is a promising tool for cancer therapy and for genetic immunization programs against infectious diseases, provided that host immune responses are carefully controlled.
Enhanced tonic GABAA inhibition in typical absence epilepsy
It is shown that extrasynaptic GABAA receptor–dependent 'tonic' inhibition is increased in thalamocortical neurons from diverse genetic and pharmacological models of absence seizures, identifying an apparently common cellular pathology in typical absence seizures that may have epileptogenic importance and highlight potential therapeutic targets for the treatment of absence epilepsy.